PBM Problems (Part 2): Transparency and Disrupting the Status Quo w/ Mutual Rx CEO Roy Wilkinson

“There’s a reason that over the last 45 years, the PBM model has been the darling of Wall Street: because it makes a heck of a lot of money for its investors.” – Roy Wilkinson

PBMs are in the hot seat: Last week, the House Committee on Oversight and Accountability pressed the CEOs of United’s Optum Rx, Cigna’s Express Scripts and CVS Caremark (the “Big 3”) on allegations of profiting from unfair practices at the expense of the American people. A recent report from the FTC also blasted the powerful middlemen for “inflating drug costs and squeezing Main Street pharmacies.” 

In a field characterized by deception and greed, we’re excited to share a “carafe is ¾ full” perspective. The MTVA Board spoke with Roy Wilkinson, a disruptor offering an alternative to PBMs. 

Roy Wilkinson is the CEO and Founder of Mutual Rx – an innovative approach grounded in trust and transparency. After working as a consultant in the field for many years, Roy and his clients were fed up with the lack of transparency and pricing games offered by conventional PBMs, and believed in a better way. 

As Roy explains, “You can’t assess value without knowing what stuff costs.” 

Mutual Rx offers self-directed solutions that empower plan sponsors to personalize their pharmacy benefits and reduce costs. The “mutual” represents their equity model, where clients can reap the benefits of managing their drug spend. Roy and his team act as fiduciaries who protect the interest of the plan and its members, not outside financial influencers. 

Tune in to learn more about how Roy and Mutual Rx are helping plan sponsors save money – reducing costs by 20% or more! 
All episodes of MTVA Unscripted can be found⁠ ⁠here⁠⁠.